Sermorelin vs Tesamorelin
Head-to-head comparison of Sermorelin and Tesamorelin for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Previously FDA-approved (Geref, discontinued); now used off-label via compounding | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Safety Profile | Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile; Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) | Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%); Headache, nausea, and flu-like symptoms reported |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 100–300 mcg/day SC | 2 mg/day SC (FDA-approved dose) |
| Frequency | Once daily (typically before bed) | Once daily |
| Molecular Weight | ~3357.9 g/mol | ~5135.9 g/mol |
| Half-Life | ~10–20 minutes | ~26–38 minutes |
Overview
Sermorelin and Tesamorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Sermorelin — Mechanism & Evidence
Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.
Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Tesamorelin — Mechanism & Evidence
It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Shared Research Applications
Both peptides are studied for: Body Composition.
Sermorelin is also researched for: Anti-Aging, Sleep.
Tesamorelin is also researched for: no additional unique applications.
Safety Considerations
Sermorelin: Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Tesamorelin: Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%) Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs Sermorelin: Comparing GHRH Analogues in Research
Compare tesamorelin vs sermorelin GHRH analogues for research. Explore mechanisms, preclinical findings, and evidence limitations.
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe